Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 119

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 6
Chunk 119
---
 2024, Mr. Hopper’s ownership percentage
decreased to 8.9% as a result of dilution following the completion of a capital raising by Radiopharm. In August 2024, Mr. Hopper’s
ownership decreased to less than 5% as a result of another capital raising. In September 2024, Mr. Hopper increased his ownership to 149,221,428
ordinary shares, representing 6.87% of the total outstanding ordinary shares.

In February 2022, NanoMab
increased its ownership from 21,111,111 ordinary shares to 26,999,909 ordinary shares. In March 2022, NanoMab increased its ownership
from 26,999,909 ordinary shares to 28,295,131 ordinary shares. In July 2024, Nanomab’s ownership percentage decreased to 3.2% as
a result of dilution following the issuance by Radiopharm to institutional and professional investors of 597,130,727 ordinary shares at
a price of A$0.04 per share with one free-attaching option per two ordinary shares issued at an exercise price of A$0.06 per option.

To our knowledge, we are not
directly or indirectly controlled by another corporation, by any foreign government or by any other natural or legal person severally
or jointly. There are no agreements known to us, the operation of which may at a subsequent date result in a change in control of Radiopharm.
All shareholders have the same voting rights.

B. Related Party Transactions

The following is a description of our related party
transactions since July 1, 2022.

In fiscal 2021, Paul Hopper
(our Chairman) loaned A$69,000 to Radiopharm to fund working capital in the Company at the time of inception. In fiscal 2022, the Company
repaid the entire loan.

In fiscal 2023 there were no related party transactions.

In fiscal 2024, the Acclime
Group invoiced Radiopharm for professional services such as financial reporting, capital management, company secretarial, accounting,
bookkeeping, and payroll activities, amounting to A$605,390. Mr. Hains, a Director of Acclime Australia, is Radiopharm’s Chief Financial
Officer and has been a Director of Radiopharm since March 2024.

In fiscal 2024, Paul Hopper